Controlling blood glucose in type 2 diabetes remains challenging. All existing drugs have significant limitations and side effects, with some causing weight gain and thereby exacerbating the condition. This short review looks at new groups of drugs on the market and under development, and discusses their potential in the management of type 2 diabetes.
Keywords DPP-IV inhibitors, hypoglycaemia, incretin mimetics, obesity, thiazolidinediones, type 2 diabetes, weight loss drugs
Declaration of Interests Prof. Wilding has received grants, consultancy and lecture fees from numerous pharmaceutical companies, including AstraZeneca, Lilly and Novo Nordisk. Both authors are investigators in trials of DPP-IV inhibitors and SGLT2 inhibitors, and Prof. Wilding is also involved in trials of GLP-1 analogues and glucokinase activators.
